FDA pushes back decision on Zevra’s drug; Revance to raise $100M

Plus, news about Io­vance Bio­ther­a­peu­tics, Nek­tar Ther­a­peu­tics, Hei­del­berg Phar­ma, Vivory­on Ther­a­peu­tics and Ab­sci:

FDA de­lays de­ci­sion on Zevra Ther­a­peu­tics’ rare dis­ease drug: The FDA will now de­cide whether to ap­prove Zevra’s treat­ment for a lyso­so­mal stor­age dis­or­der called Nie­mann-Pick dis­ease type C by Sept. 21, three months lat­er than an ini­tial de­ci­sion dead­line in June. Zevra had sub­mit­ted ad­di­tion­al in­for­ma­tion for ari­mo­clo­mol, which is a small mol­e­cule med­i­cine de­liv­ered three times a day. The com­pa­ny’s stock $ZVRA was down about 11% on Mon­day morn­ing. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.